France to Release 10 Million Barrels of Diesel to Ease Fuel Prices 
Judge Blocks Trump Election Conditions on Counterterrorism Grants 
Japan Real Wages Rise 1.5%, Supporting BOJ Rate Hikes 
Evan Gershkovich Says FSB Set Trap for 2023 Russia Arrest 
S&P 500 Hits Record High as AI Rally Lifts Wall Street 
Venezuela Nears Deal to Move $4 Billion in Gold to New York Fed 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
Oil Prices Rise as Hormuz Attacks Fuel Supply Fears 
Lincoln University Students Sue Missouri Over Decades of Underfunding 
Fed Minutes Signal Another Rate Hike by Year-End 
Florida Seeks Tougher Meta Rules to Protect Young Users 
Deere, CNH and AGCO Stocks Fall as FTC Launches Farm Equipment Probe 
Gold Prices Slip as Strong Dollar and High Treasury Yields Weigh 
European Stocks Fall as Oil Rises Ahead of Fed Minutes 
Trump Asks Supreme Court to Restore Third-Country Deportations 
Colombia Extradites FARC Dissident Leader ‘Spider’ to US 
Oil Prices Rise as Hormuz Risks Offset IEA Stock Release 
Add as a preferred source on Google
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
